



Rh PROGRAM of NOVA SCOTIA

5850 / 5980 University Avenue, PO Box 9700
Halifax, Nova Scotia, Canada, B3K 6R8
Tel: (902) 470-6458 Fax: (902) 470-7468 http://rcp.nshealth.ca/rh

Rho(D) IMMUNE GLOBULIN (WinRho®SDF) INJECTION REPORTING FORM

Mother's Surname: _____ Mother's First Name: _____

Mother's Maiden Name: _____ Mother's ABO & Rh type: _____

Mother's Date of Birth: _____ / _____ / _____ Health Card #: _____
DD / MM / YY

Expected Date of Delivery: _____ / _____ / _____ Mother's address: _____
DD / MM / YY

Treating Health Professional*/Clinic: _____

- NOTE:**
1. An antibody screen should be drawn *within two weeks* **PRIOR TO** THE ADMINISTRATION OF Rho(D) IMMUNE GLOBULIN (WinRho®SDF).
 2. WinRho®SDF is a BLOOD PRODUCT. Has consent been obtained by the physician, nurse practitioner or midwife? No Yes
 3. Maintain close observation (15 to 30 minutes post administration) for any adverse reactions.

Previous known reactions to blood products?

No Yes If yes, describe: _____

REASON FOR INJECTION (please check):

Antepartum (28 weeks)

Amniocentesis

Ectopic Pregnancy

Antenatal Bleeding (threatened miscarriage)

Miscarriage

Termination of Pregnancy @ _____ weeks

Platelet Transfusion

Postpartum

Delivery Date: _____ / _____ / _____
DD MM YY

Infant's ABO group: _____ Rh type: _____

Maternal KLEIHAUER test:

NEG: _____ POS: _____ % fetal cells: _____

Other indication (Please explain): _____

DATE ADMINISTERED: _____ (DD/MM/YY) **Hospital/Clinic:** _____

GIVEN BY (Signature): _____ **(Print Name):** _____

Route: _____ **Lot No:** _____ **Dosage:** _____ µg (or _____ I.U.)

WHITE COPY (original): Patient's Chart

YELLOW COPY: Rh Program of Nova Scotia

PINK COPY: Hospital Transfusion Service (laboratory)

*Physician/Nurse Practitioner/Midwife

Form 7048 03/2015 3-part NCR

Revised March 2015



NSRHIF